Alginate based tamoxifen/metal dual core-folate decorated shell: Nanocomposite targeted therapy for breast cancer via ROS-driven NF-κB pathway modulation

Int J Biol Macromol. 2020 Mar 1:146:119-131. doi: 10.1016/j.ijbiomac.2019.12.266. Epub 2020 Jan 3.

Abstract

Breast cancer endocrine resistance prevents unleashing full capabilities of Tamoxifen (TMX), besides TMX off-target side effects on healthy tissue. In this study, we engineered TMX nanocomposite via co-loading it on alginate-based silver nanoparticles and embedding within folic acid-polyethylene glycol surface conjugate. The coating process was done by w/o/w double emulsion method. To confirm the silver nanoparticles formation, UV spectroscopy, XRD and TEM analysis were carried out. TEM results confirmed the core-shell structure of folate targeted nanocomposite with approximate average diameter of 66 nm, the nanocomposite structures were characterized by FTIR, TGA and SEM. By comparing with the non-targeted formula, folate decorated formula had 12-folds lowered IC50 value and 12.5-14-fold higher cancer cells toxic selectivity index. Also, after 4 h treatment, both fluorescence microscopic and flow cytometric analysis indicated higher intracellular accumulation of folic acid conjugated formula on MCF-7 cancer cells than the non-targeted one with 3.44-folds. The breast cancer cytotoxic effects of this metal-endocrine nanocomposite formula could be explained by the induction of reactive oxygen species (ROS), down regulation of survival oncogenic genes (BCL-2 and Survivin) and the accumulation of MCF-7 cells in G2/M phase. All these data confirm the efficiency and efficacy of the formulated nanocomposite as future treatment for breast cancer.

Keywords: Breast cancer; Cancer targeting; Folic acid coated PEG; Metal-endocrine nanocomposite; Tamoxifen.

MeSH terms

  • Alginates / chemistry
  • Alginates / pharmacokinetics
  • Alginates / pharmacology
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Drug Carriers* / chemistry
  • Drug Carriers* / pharmacokinetics
  • Drug Carriers* / pharmacology
  • Female
  • Humans
  • MCF-7 Cells
  • NF-kappa B / metabolism*
  • Nanocomposites* / chemistry
  • Nanocomposites* / therapeutic use
  • Neoplasm Proteins / metabolism*
  • Reactive Oxygen Species / metabolism*
  • Silver / chemistry
  • Silver / pharmacokinetics
  • Silver / pharmacology
  • Tamoxifen* / chemistry
  • Tamoxifen* / pharmacokinetics
  • Tamoxifen* / pharmacology

Substances

  • Alginates
  • Drug Carriers
  • NF-kappa B
  • Neoplasm Proteins
  • Reactive Oxygen Species
  • Tamoxifen
  • Silver